CALIFORNIA ASSOCIATION OF TOXICOLOGISTS
Saturday, August 2, 2003

Site: Vineyard Creek Hotel, Spa & Conference Center
170 Railroad Street
Santa Rosa, CA 95401
Ph: 707-636-7100
Fax: 707-636-7130
www.vineyardcreek.com

Host: Gregory A. Priebe
California Department of Justice
Santa Rosa Criminalistics Laboratory
7505 Sonoma Highway
Santa Rosa, CA 95409
707-576-2415
www.Cal-tox.org

PRELIMINARY AGENDA

08:00 – 09:00  REGISTRATION & CONTINENTAL BREAKFAST

08:30 – 09:00  BUSINESS MEETING

09:00 – 09:30 Christine Moore, Ph.D. Laboratory Director, United States Drug Testing Laboratories, Des Plaines, IL. Analytical Diagnosis of Fetal Alcohol Exposure

09:30 – 09:45  BREAK

09:45 – 11:45 Wayne Jones Ph.D., Department of Alcohol Toxicology, National Laboratory of Forensic Chemistry, Linkoping, Sweden. Pharmacodynamics and Pharmacokinetics of Alcohol


12:15 – 13:30 LUNCH

13:30 – 14:15 Arthur L. Klatsky, MD Senior Consultant in Cardiology Kaiser Permanente Medical Center, Oakland, CA. Alcohol and Cardiovascular Diseases: A Historical Perspective.

14:15 – 15:00 Martin Mumenthaler, Ph.D. Stanford University School of Medicine, Palo Alto, CA. Gender differences in the effects of alcohol and the role of the menstrual cycle.

15:00 – 15:15 BREAK

15:15 – 16:15 Michael Laposata, MD, PhD Professor of Pathology, Harvard Medical School Director of Clinical Laboratories, Massachusetts General Hospital, Boston, MA. Fatty acid ethyl esters as postmortem markers for premortem ethanol intake.

16:15 – 17:00 Daniel Isenschmid Ph.D. Chief Toxicologist, Wayne County Medical Examiner, Detroit, MI. Postmortem Alcohol issues

The AACC will probably approve this workshop for 6 ACCENT Credits. AACC ACCENT CREDIT IS GIVEN ONLY FOR ATTENDANCE DURING A WHOLE SESSION.
Please read the following carefully and in full. Pre-registration Deadline for the Quarterly Meeting is Friday, July 18, 2003, two weeks prior to the meeting date. Both correct payment-in-full and the pre-registration form must be received by July 18, 2003 to avoid the late fee and assure that lunch is included. Please do not fax “intent” to register. Payment by mail or at the meeting must be by check or cash—no credit or ATM cards are accepted. Pre-registration received after July 18 is charged a $10 late fee per session. Payment cannot be refunded for cancellations received after July 18. There is no written acknowledgment of pre-registration prior to the meeting unless a self-addressed stamped envelope accompanies payment. NOTE: Late pre-registration, incorrect payment, lack of forms, and forms with no payment are an increasing problem and cost to CAT. Please verify in a timely fashion that your company/employee(s) registers correctly by the deadline. Walk-in attendance for the Quarterly Meeting depends on seating capacity, but is usually possible. However, the $10 late fee is assessed and no lunch is guaranteed. Mail the pre-registration form(s) and payment to: Judy Rector- CAT Assistant, P.O. Box 52335, Livonia, MI 48152; Telephone: (734) 634-9182. Make check payable to “CAT”.

All hotel room reservations at the Vineyard Creek Hotel, Spa & Conference Center– Santa Rosa must be placed before July 01, 2003 and you must identify yourself with CAT to ensure the reduced rate per night plus tax as follows. Reserve room by directly calling the Vineyard Creek Hotel – Santa Rosa at 1-888-920-0008 or 707-636-7100.

Directions:
From Oakland take I-880 North toward Berkeley, take the I-580 exit toward Richmond/San Rafael, continue over the toll bridge and take US-101 North (37 miles to Santa Rosa). In Santa Rosa take the downtown exit, left at the light onto 3rd street, the second stop light is Railroad – take a left.

------------------------------------------------------------------------------------------------------------------

CAT QUARTERLY MEETING & REGISTRATION FORM: Friday & Saturday, August 1 & 2, 2003

Quarterly Meeting, Friday, August 1, 2003:
( ) $65.00 pre-registered CAT Member ($75.00 after July 18, 2003)
( ) $40.00 pre-registered CAT Emeritus Member ($50.00 after July 18, 2003)
( ) $75.00 pre-registered Non-CAT Member ($85.00 after July 18, 2003)

Quarterly Meeting, Saturday, August 2, 2003
( ) $65.00 pre-registered CAT Member ($75.00 after July 18, 2003)
( ) $40.00 pre-registered CAT Emeritus Member ($50.00 after July 18, 2003)
( ) $75.00 pre-registered Non-CAT Member ($85.00 after July 18, 2003)

Enclosed is the total pre-registration of $__________.

Name:___________________________________________________________

Professional (Business) Affiliation:___________________________________________

Address:___________________________________________________________________ Phone:__________________________
Thanks to Vendors!

On behalf of C.A.T., we would like to thank the following vendors for their tremendous support at our Albuquerque meeting. The combined sponsorships generated $13,500 in revenue. In addition, door prizes were provided by UCT Laboratories, VertiQ Software, Cerrilant, and Immunalysis. Now show your support by utilizing these contacts when you are in need of new supplies and equipment!

Michelle Sandberg, C.A.T. Vendor Coordinator

<table>
<thead>
<tr>
<th>Exhibitors</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andwin Scientific</td>
<td><a href="www.andwin.com">www.andwin.com</a> (800) 497-3113</td>
</tr>
<tr>
<td>Biochemical Diagnostics, Inc.</td>
<td><a href="www.biochemicaldiagnostics.com">www.biochemicaldiagnostics.com</a> (800) 223-4835</td>
</tr>
<tr>
<td>Capitol Vial, Inc.</td>
<td><a href="www.capitolvial.com">www.capitolvial.com</a> (800) 772-8871</td>
</tr>
<tr>
<td>Cozart Bioscience Inc.</td>
<td><a href="www.cozart.biz">www.cozart.biz</a> (859) 271-5909</td>
</tr>
<tr>
<td>Full Spectrum Analytics, Inc.</td>
<td><a href="www.fullspectrum-inc.com">www.fullspectrum-inc.com</a> (800) 795-6357</td>
</tr>
<tr>
<td>Immunalysis Corp.</td>
<td><a href="www.immunalysis.com">www.immunalysis.com</a> (888) 664-8378</td>
</tr>
<tr>
<td>OraSure Technologies, Inc.</td>
<td><a href="www.orasure.com">www.orasure.com</a> (800) 869-3538</td>
</tr>
<tr>
<td>Neogen Corporation</td>
<td><a href="www.neogen.com">www.neogen.com</a> (800) 477-8201</td>
</tr>
<tr>
<td>PerkinElmer Instruments</td>
<td><a href="www.perkinelmer.com">www.perkinelmer.com</a> (800) 762-4000</td>
</tr>
<tr>
<td>Speware Corp.</td>
<td><a href="www.speware.com">www.speware.com</a> (310) 831-0018</td>
</tr>
<tr>
<td>Thermo Nicolet &amp; ThermoFinnigan</td>
<td><a href="www.thermonicolet.com">www.thermonicolet.com</a> (800) 648-5456</td>
</tr>
<tr>
<td>Utak Laboratories, Inc.</td>
<td><a href="www.utaklabs.com">www.utaklabs.com</a> (800) 497-3113</td>
</tr>
<tr>
<td>VertiQ Software, LLC</td>
<td><a href="www.vertiQ.com">www.vertiQ.com</a> (408) 778-0608</td>
</tr>
<tr>
<td>Varian, Inc.</td>
<td><a href="www.varian-onsite.com">www.varian-onsite.com</a> (800) 737-9667</td>
</tr>
</tbody>
</table>
The California Association of Toxicologists has made available $2,500 for a Research Assistance Grant. This grant is intended to fund research projects in the area of clinical and forensic toxicology. In addition, up to $500 is available for travel expenses to recipients of the grant who will be expected to present their findings at a future CAT meeting. For further information contact the Chair of the CAT Research Assistant Grant by fax, mail or email at the address below.

Robert L. Fitzgerald, Ph.D.
VAMC-113
3350 La Jolla Village Dr.
San Diego, CA 92161

Phone: (858) 552-8585 x 7761
Fax: (858) 642-6304
rlfitzgerald@vapop.ucsd.edu
CAT QC/QA SPECIMEN SURVEY

The QC/QA program exists because of strong involvement with 38 laboratories over 14 different states participating in this unique inter-laboratory exchange proficiency program. It has become a way for host laboratories to test participants on problematic analytes or a way to introduce new drugs or trends that they are experiencing in their geographical region. There is minimal amount of work involved with hosting a proficiency sample and volunteers are obviously needed to keep this program striding in the right direction. If you are interested in hosting a survey or participating in the CAT proficiency sample, please contact

Dan Anderson (323) 343-0530 or e-mail Danderso@co.la.ca.us.

How can I join?

1. Your laboratory must be in the U.S. or Canada.
2. The analyst (or at least one member of the laboratory) must be a member of the California Association of Toxicologists (CAT).
3. Turn in the half-sheet below to Dan Anderson (Quality Assurance Chair, CAT).

Dan Anderson
Los Angeles County Dept. of the Coroner
1104 North Mission Rd.
Los Angeles, CA 90033
323-343-0530
323-225-2235 FAX
Danderso@co.la.ca.us

-----------------------------------------------------------------------------------------------------------------------------------------------

YES, I wish to join the CAT Survey. My laboratory analyzes:

☐ Urine      ☐ Serum      ☐ Whole Blood
☐ Drugs of Abuse       ☐ Broad Spectrum Screening

Name___________________________________________________
Lab_____________________________________________________
Address__________________________________________________

Phone _____________________________ FAX

☐ I am not a member of the CAT. I have attached an application form.*

*A Membership Application Form and explanation of membership requirements is enclosed in this Proceedings; see "Forms."


**Future Meetings & Short Courses**

**American College of Clinical Pharmacology 32th Annual Meeting, September 21-23, 2003, Tampa, FL.** Contact: Susan Ulrich, ACCP Executive Director, 3 Ellinwood Court, New Hartford, NY 13413-1105, (315) 768-6117, fax (315) 768-6119, e-mail: ACCP1ssu@aol.com

**European Academy of Forensic Science, September 22-27, 2003, Istanbul, Turkey.** Contact: EAFS 2003 Istanbul Meeting Secretariat, ODS Tourism & Travel Ltd., Yildiz Cicegi Sokak 12/1 Etiller, 80630 Istanbul, Turkey, (+90 212) 28758 00, fax (+90 212) 263 45 81, eafs2003@enfsi.org


**HPLC 2004 - 28th International Symposium and Exhibit on High Performance Liquid Phase Separations and Related Techniques, June 12-18, 2004, Philadelphia, PA.** Contact: Janet Cunningham, Barr Enterprises, P.O. Box 279, Walkersville, MD 21793, (301) 898-3772, fax (301) 898-5596, janetbarr@aol.com

**2004 FBI Laboratory Forensic Toxicology Symposium & Joint Meeting of the Society of Forensic Toxicologists (TIAFT), August 28-September 3, 2004, Portland, OR.** Contact: Marc A. LeBeau, Federal Bureau of Investigation, FBI Laboratory, (202) 324-8472, fax (202) 324-4633, mlebeau@fbi.gov

**American College of Clinical Pharmacology 33th Annual Meeting, October 3-5, 2004, Chicago, IL.** Contact: Susan Ulrich, ACCP Executive Director, 3 Ellinwood Court, New Hartford, NY 13413-1105, (315) 768-6117, fax (315) 768-6119, e-mail: ACCP1ssu@aol.com

**California Association of Toxicologists Board of Directors Meeting May 2, 2003 Albuquerque, New Mexico**

The meeting was convened at 7:30 pm. Board members present were Dea Boehme, Jim Meeker, Bill Phillips, John Hughes, Bob Taylor, and Sam Le. Also present were Sarah Kerrigan, local meeting host, committee chairs Dan Anderson, Cathy Hamm, Michelle Sandberg, and incoming Treasurer Kristina Fritz and incoming MAL-South Tiffany Kuwahara. Guests Derelle Phillips and Garth Kerrigan were welcomed. Minutes of the previous board meeting were approved by a voice vote.

**President’s report**

The current economic downturn is continuing to affect public forensic laboratories throughout the country. The membership will be advised at the business meeting about certification opportunities with ABC (criminalists) and ABFT or SOT (toxicologists). Dea thanked the outgoing board members and committee chairs for their support during her service.

**Vice-President’s report**

Jim Meeker thanked Dea for her service, and Sarah Kerrigan for organizing this joint meeting, with its extra complication of coordinating with another society. He will bring to a vote of the membership the previously published proposal of going to three meetings per year (proposed to be March, June-July and November, rotating between northern Calif, southern Calif and an out-of-state location when feasible). The meeting hosts for the next two meetings have requested $500 for invited speaker travel expenses. The board agreed to this as long as the expense is covered by meeting income.

**Past-President’s report**

Bill Phillips thanked the board and the nominated candidates for office, for taking the personal time to support our organization.

Bill reported that a prototype web site has been established for electronic publication of the Proceedings. This was accomplished using the ISP that hosts the CAT Toxicology Literature Review via a link from the CAT home page. The committee contracted with Jeff Lee, one of the bidders discussed at the last board meeting, to design the page and post pdf versions of the Proceedings and speaker presentations. John Hughes prepared the February materials which were posted. Bill showed the web site on his laptop, and reported that viewing speed appears to be satisfactory. The May Proceedings will be posted, tested and then the membership will be notified in a mailing of its availability and the password required to access the material. Future plans are for the archived Proceedings to be searchable by keyword, but this is not currently in the contract with Jeff Lee. There currently is a password/logon problem that will have to be fixed before further testing by board and committee members. Dea, Kristina, Bob and Dan volunteered to help with that testing.

**Membership Secretary’s report**

Greg Priebe who was unable to attend the meeting, forwarded candidates for Associate and Full membership and one member reclassification to Emeritus. All were approved by the board to be voted on by membership, and their roster information is published in the minutes of the business meeting.

**Recording Secretary’s report**

A colored flyer for the August meeting in Napa hosted by Greg Priebe, with meeting agenda, registration form, and hotel reservation info will be sent out ahead of the proceedings to ensure plenty of notice to members. The annual dues notice will be included in this mailing to save costs and ensure timely payment of dues by July 1. An improved dues form to capture roster updates, and to determine which members without Internet access will require a paper copy of Proceedings, will be designed by Proceedings and Membership secretaries in consultation with the treasurer.

**Treasurer’s report**

Sam Le reported that CAT finances are in good shape. The February meeting actually showed a positive balance due to unexpectedly good turnout (lots of walk-ins) and good vendor support. The Proceedings are less costly than last year due to Judy Rector handling the production and mailing, rather than...
using the mailing service that had been used in southern California. The third quarter showed a small deficit because of fewer dues payments, but included $460 in income from video rentals for continuing education. The details are published immediately following the minutes along with last quarter’s report.

**Member-at-Large, North: Dan Coleman**

Dan was unable to attend the meeting but sent the following report:

CCI Liaison - In early April, I sent an e-mail to Victor Reeve, head of CCI, as a means of introduction and to get a feel for their status. I have not heard back from him. We are waiting to hear from him before searching for another contact there with which to liaze.

I contacted Alan Barbour regarding my plan for a information exchange link on the C.A.T. website. He thought it would be easy enough to make happen. I will wait for the outcome of the board’s decision on a new website before making any modifications to the site. In the mean time, I plan on contacting members regarding equipment usage in their laboratories.

I have begun the process of requesting a new drug (lamotrigine or Lamictal) standard for our lab. It is used in the treatment of epilepsy, and has been around for a few years. The drug is made by GlaxoSmithKline. I have contact info for anyone wishing a sample for their lab.

Disposition of Toxic Drugs and Chemicals in Man has come out with a sixth edition. The e-mail address is biopub@lycos.com. It is considerably larger than the previous edition with a lot of antibiotics, nerve agents, and herbal poisons.

**Member-at-Large, South: Bob Taylor**

1. Assembly Bill 506
   Introduced by Assembly Member Maze
   An act to amend Section 13823.11 of the Penal Code, relating to sexual assault victims.

   Existing law sets forth minimum standards for the examination and treatment of victims of sexual assault, including the collection of physical evidence. This bill would provide, in addition and subject to the victim’s refusal, that where indicated by the history of the contact, the victim’s urine and blood sample would be collected for toxicology purposes, to determine if drugs or alcohol were used in connection with the assault. The bill would prohibit imposing sanctions against an individual based solely on these toxicology findings, and would require that victims be informed of specified information regarding the testing.

   Issues of concern are the additional cost to local governments to provide this testing and the actual need for this bill since sexual assault examiners should have training on when drug testing is appropriate. As of April 30, 2003, the Committee on Appropriations passed the Bill 24-0.

2. The UCLA Summer Conference is hosting “Current Topics in Forensic Toxicology” from August 21-23, 2003.
   Day 1 - August 21st: Alcohol, Cocaine, Methamphetamine, and Marijuana Issues
   Day 2 - August 22nd: Forensic Science and Terrorism
   Day 3 - August 23rd: Raves and Current Drug Trends
   Application has been made to the American Association for Clinical Chemistry, Inc. for ACCENT credit.
   More information can be obtained from the CAT website or after May 8, from the UCLA Extension website.

   It has been a pleasure serving on the CAT Board for the last three years. Thank you for your support and I’ll see you at the next meeting.

**AACC ACCENT Credits- Continuing Education**

Cathy Hamm reported that Kenton Wong, San Mateo County Sheriff’s lab, will be taking over ACCENT credit arrangements from her. The AACC certification process has become easier with the use of electronic forms from the website.

**Lending Library**

Cathy Hamm has taken over the Lending Library from Russ Lowe.

**QA/QC CAT Proficiency Survey**

Chair Dan Anderson reported that he is tracking non-responding labs, which will be dropped from the survey, so that extra work in sample preparation is not wasted on them. In recruiting labs to prepare the survey sample, he publicizes the drugs in previous surveys to keep the material fresh and challenging.

**Vendor Coordinator**

Michelle Sandberg reported that there have recently been difficulties with some aspects of vendor support for meetings. For this meeting, there was a conflict with a vendor’s sponsorship of the social event, in which the vendor was dealing directly with the hotel (had cost problems) and in which a vendor objected to co-sponsoring an event with a competitor.

The Vendor Coordinator has prepared an updated Vendor Guidelines for Meeting Hosts which will be published in the Proceedings, and included in the Policies and Procedures manual and Meeting Host materials. The most important instruction to meeting hosts is DO NOT make commitments to vendors without consulting the CAT Vendor Coordinator. Another important vendor policy is “first-come, first-served” for both attending meetings and sponsoring social events. We need to make vendor sponsorship as easy as possible for vendors, and to work with their concerns for cost and competitors.
Local host report

Sarah Kerrigan, CAT host for the May CAT-SAT joint meeting in Albuquerque, reported that the pre-registrations accounting for $7200 and on-site on Friday for $3500. The income over expenses for the meeting will be distributed between CAT and SAT according to the ratio of CAT and SAT members registered for the meeting.

Other meeting policy discussions

The board discussed and agreed to the following policies regarding meeting registration:

1. Elected board members (not committee chairs) are entitled to free meeting registration, but must notify the office of their attendance so that space and lunch is provided.

2. Meeting host has discretionary use of free registrations for up to five members of his/her organization who work on the meeting, as long as meeting income and expenses permit.

3. Incoming President and Vice-President Jim Meeker and Sarah Kerrigan will be reviewing and updating the meeting host guidelines binder. It has been reported by recent meeting hosts that they have not received it, or it has been too long and detailed to be useful.

The meeting was adjourned at 9:30 pm.

Respectfully submitted,

John Hughes
Recording Secretary/Proceedings Editor

California Association of Toxicologists
12-01-02 TO 02-28-03

BEGINNING BALANCE: 27,576.27

INCOME
Membership Dues(2002-2003) 1,080.00
February, 2003 Meeting Registration 4,850.00
Continuing Education 460.00
November, 2002 Meeting (Sponsor) 500.00
Interest 12.40

TOTAL INCOME 6,902.40

EXPENSES
CAT Assistant 2,000.00
Proceedings –
November, 2002 2,296.47
Meeting Expenses –
February, 2003 Meeting 4,660.93
Meeting Expense –
November, 2002 Meeting 97.95
Continuing Education 511.49
State of California 20.00

TOTAL EXPENSES 9,586.84

INCOME – EXPENSES <2,684.44>

ENDING BALANCE 24,891.83

MONEY MARKET 14,052.56

California Association of Toxicologists
Report For February, 2003 Meeting

INCOME
Registration 4,850.00

TOTAL INCOME 4,850.00

EXPENSES
Meeting Room & Meals 3,822.28
Speaker’s Expenses 825.00
Postage 13.65

TOTAL EXPENSES 4,660.93

INCOME – EXPENSES 189.07
Vendor Sponsorships: Guidelines for the meeting Host

1. Provide the C.A.T. vendor coordinator with the following information:
   1.1. Meeting dates and Hotel location
   1.2. Technical program topics/agenda
   1.3. Location of exhibitor tables (preferably inside the meeting room)
   1.4. Maximum number of exhibitors the facility can handle

2. If you plan to have a social event on Friday evening, you need to choose one of the following:
   2.1. You organize and plan the event. Vendors will be solicited to sponsor ($1000.00) or co-sponsor the event ($500.00). If the expenses exceed the sponsorships, you need to budget accordingly. Please check with the Vendor Coordinator to be certain you have the latest fee schedule.
   OR
   2.2. Vendors are solicited to plan, organize, and host the event. The location, budget, etc. would be at the vendor’s discretion, as they would pay the facility directly. The host has no responsibilities other than advertising. If more than one vendor has indicated an interest in hosting/co-hosting the event, the first post-marked contract received by the vendor coordinator will be honored.

2. Once #1 and #2 have been decided and communicated to the Vendor Coordinator, an exhibitor contract will be assembled.
   2.1. You will be given a copy of the exhibitor contract. Please do not edit/change this form.
   2.2. The vendor coordinator’s responsibilities include recruitment, collecting contracts, money, and obtaining AACC forms.
   2.3. Tables and sponsorships are reserved on a first come, first serve basis. Hence, please do not make any promises to vendors without the consent of the vendor coordinator.

3. Before the meeting:
   2.4. Obtain a list of all the vendors that will be attending, and include them on your name tag list.
   2.5. When preparing your budget, be sure to account for the vendors at breaks and lunches.
   2.6. Please schedule 15 minutes at the beginning of Friday’s program for Vendor Introductions
**California Association of Toxicologists**  
**Business Meeting**

May 3, 2003  
Albuquerque, NM

The meeting was called to order at 8:30am by president Dea Boehme.

The president reported the continuing financial crisis of many tox labs in the current economic climate, particularly in city, state and county agencies, and reminded members of posting positions via the CAT forum which can be joined from the website.

Dea pointed out certification opportunities for labs with ASCLAD, and for personnel with ABC (crime labs) and both ABFT and the AACC National Registry for toxicologists. The ABFT exam is being given during this meeting.

Vice President Jim Meeker proposed a change in the CAT Bylaws as discussed at the last meeting, and published in the Proceedings. It was moved, seconded and passed by a unanimous show of hands (of full members present), that there shall be a minimum of 2 and up to 4 meetings per year with the number and location chosen by the elected Board of Directors.

Jim presented the plan for the coming year: meetings in March, July and November 2004, alternating between northern and southern California locations and one out-of-state location (previous examples: Reno, Las Vegas, Tempe) when appropriate. By-laws chair Halle Weingarten will be directed to update the By-laws.

Candidates for CAT membership were presented by Jim Meeker on behalf of Membership Secretary Greg Priebe who could not attend the meeting.

Changes to Membership  
Membership Secretary Greg Priebe

The following members were presented and approved by voice vote at the May Business meeting.

**Associate Membership**  
**Roster Information:**

Members Name: M.L. Pierson  
Degrees: Bachelor of Science Chemistry, University of San Diego, MS Quality Assurance, California State University Dominguez Hills  
Name of Business: Forensic Science Consulting Group  
Business Address: 10366 Roselle St.  
San Diego, CA 92121  
Business Title: Forensic Chemist  
Business Phone: 858-453-7121  
Fax:  
Electronic Mail: sleuthlab@nethere.com  
Mailing Address: 10366 Roselle St.  
San Diego, CA 92121

Roster Information:  
Members Name: Dorothy Guintu

Degrees:  
Name of Business: Quest Diagnostics  
Business Address: 7600 Tyrone Ave. Van Nuys, CA  
Business Title: Certifying Scientist  
Fax: 805-498-1038  
Electronic Mail: dguintu@hotmail.com  
Mailing Address: 13 Nadine Court  
Newbury Park, CA 91320

Re-classification to Full Member

Roster Information:  
Members Name: Tiffany Kuwahara  
Name of Business: Los Angeles County Sheriff’s Department  
Business Address: 7717 Golondrinas St.  
Downey, CA 90242  
Business Title: Business Phone: 562-940-0158  
Fax: 562-940-0366  
Electronic Mail: tfkuwaha@lasd.org  
Meetings Attended: August 2001 – Berkeley, CA and May 2003 Albuquerque

Sponsors: Robert Taylor and Sam Le

Roster Information:  
Members Name: Kristina Fritz  
Name of Business: Los Angeles County Department of Coroner  
Business Address: 1104 N. Mission Rd  
Los Angeles, CA 90033  
Business Title: Business Phone:  
Fax:  
Electronic Mail: kfritz@co.la.ca.us  
Meetings Attended: May 2002 – Tempe, AZ and August 2002 – San Jose, CA

Sponsors: Joseph Muto and Sam Le

Roster Information:  
Members Name: Shana Meldrum  
Degrees:  
Name of Business: Contra Costa County Crime Lab  
Business Address: 1960 Muir Rd.  
SAN RAFAEL, CA 94901  
Business Title: Business Phone:  
Fax:  
Electronic Mail:  
Meetings Attended: February 2002 – San Jose, CA and February 2003 – Oakland, CA Nivan Gill and Denise Allen

Sponsors: 1463 Ashwood Dr. Martinez, CA 94553
Roster Information:
Members Name: Julie Fry

Degrees: BS Biology, San Francisco State University

Name of Business: National Medical Services
Business Address: 1600 Harbor Bay Parkway, Suite 150
Alameda, CA 94502

Business Title: Forensic Toxicologist

Business Phone: 510-337-3125
FAX: 510-337-3100
Electronic Mail: Julie.fry@nmslab.com
Sponsors: Judy Stewart and Randy Chang

Mailing Address: 1600 Harbor Bay Parkway, Suite 150
Alameda, CA 94502

Roster Information:
Members Name: Janet Anderson-Seaquist

Degrees: BS Biology, Arizona State University, MS Forensic Toxicology, University of Florida, Gainesville

Name of Business: Ventura County Sheriff’s Dept. Forensic Sciences Lab
Business Address: 800 S. Victoria Ave.
Ventura, CA 93009

Business Title: Supervising Forensic Scientist
Business Phone: 805-662-6804
FAX: 805-662-6717
Electronic Mail: janet.seaquist@mail.co.ventura.ca.us
Meetings Attended: Nov. 2001, Santa Barbara and Nov. 2002 Ventura
Sponsors: Dea Boehme and Anne ImObersteg

Mailing Address: 800 S. Victoria Ave.
Ventura, CA 93009

Request for Reclassification to Member Emeritus
Members Name: A. George Goehring
Mailing Address: 9617 Cider Hill Road
Redding, CA 96001
Phone Number: 530-247-1435
Member Since: 1974

Past-President Bill Phillips updated the membership of the status of electronic publication of the Proceedings. Bill showed the prototype of the web page which allows password-protected access to the Proceedings. The web-based proceedings is being tested for speed and security by board members and committee chairs, and then will be made available to paid members by distribution of the URL and password by mail. We will continue to publish and mail the Proceedings to all members for one or two more meetings until the website is well-tested. Members without Internet access will still be able to obtain a paper copy of the Proceedings by so indicating on their annual dues statement.

Bill thanked the board for approving this move, past-president Rob Fitzgerald for driving and chairing the effort, and John Hughes for helping design the site and formatting the proceedings for electronic publication.

Secretary for Proceedings John Hughes reminded the membership that any members with dues problems (last year’s check did not clear) or not receiving the Proceedings to PLEASE contact the office for resolution of those problems. The dues notice being mailed in May will include an opportunity to update roster information, and a new Membership directory will be published this summer.

Treasurer Sam Le reported that the overall financial condition of CAT continues to be excellent. The last meeting not only broke even and showed a slight positive balance. His detailed reports will be in the Proceedings. The membership thanked him for his service as treasurer with a round of applause.

Member-at-Large South Bob Taylor reported that CA Assembly bill 506 was passed by the Appropriations committee and returned to the Assembly for vote. The bill calls for collection of blood and urine samples from victims of sexual assault (with victim refusal rights), to facilitate investigation. The potential financial impact to local jurisdictions is cost and manpower to supply kits for sampling, and to determine the contents thereof.

Bob also called attention to the UCLA Extension program’s Summer Conference on Forensic Toxicology, to be held August 21-23. Information will be available shortly on the UCLA Extension website.

QA/QC Chair Dan Anderson presented the results of the Winter proficiency survey (details published in the Proceedings). The Spring 2003 proficiency sample will be prepared and distributed by the Ohio State Dept of Health. There are currently 39 laboratories participating in the CAT survey: 23 in California, 15 from other states and 1 from Canada. Repeated failure to return results from the proficiency sample will result in a lab being dropped from the distribution.

Dan presented a new drug, Abilify®, aripiprazole, a new antipsychotic with a MW of 448. Details will be included in the Proceedings.

Vendor Coordinator Michelle Sandberg thanked the many vendors present for their support of this and other meetings.

Michelle then presented on behalf of the board and the membership, a thank-you gift to outgoing president Dea Boehme for her service to CAT. This was reinforced by a round of applause.

Election of officers for 2003-2004
President Dea Boehme presented the slate of officers that had been announced at the previous meeting and in the Proceedings:

President: Jim Meeker, toxicology consultant
Vice-President Sarah Kerrigan, New Mexico Dept
agreed to take over this position after the August meeting.

Kenton Wong from the San Mateo County Sheriff’s Lab has

application deadline.

efficient and we are having no trouble meeting the 30 day
director. This has made the application process much more

for and determine the required
qualifications for a category of "certified phlebotomy technicians." In the context of clinical laboratory work, certified phlebotomy technicians generally may not withdraw blood unless supervised by a physically available physician, and surgeon, nurse, or clinical laboratory licensee. This bill would permit a person who has been issued a "certified phlebotomy technician" certificate to withdraw blood in any location and without certain locations with general supervision, as defined, at the direction and in the presence of a peace officer, for forensic purposes regardless of whether the person is employed by a clinical laboratory. This bill would add "agencies" to those parties provided this immunity.

It was moved, seconded and passed by a unanimous voice vote to accept the slate as nominated.

The meeting was adjourned to the scientific sessions at approximately 9:30 am.

Committee Reports

AACC ACCENT Credits: The May, 2003 meeting in Albuquerque was approved for 11.5 credits. The August 2003 meeting in Santa Rosa will probably be approved for 12 units.

The speaker forms are now available in print or electronic form at www.aacc.org and can be emailed directly to the program director. This has made the application process much more efficient and we are having no trouble meeting the 30 day application deadline.

Kenton Wong from the San Mateo County Sheriff’s Lab has agreed to take over this position after the August meeting.

Drugs and Driving Committee Report
Janet L. Anderson-Seaquist

We all mourn the loss of Dr. Robert F. Borkenstein. He was an active member of the NSC’s Committee on Alcohol and Other Drugs for nearly 60 years and passed away on August 10, 2002. A memorial dinner was held in Chicago during the February AAFS meeting. The NSC Committee is in the process of submitting for adoption as a National Safety Council policy its long-standing position on driving impairment at alcohol concentrations of 0.08 and above. The position/policy states that “Every person, regardless of that person’s experience with alcohol beverage consumption, is impaired in driving performance if that person’s alcohol concentration * is 0.08 or more.” *Alcohol concentration means either grams of alcohol per 100ml of blood or grams of alcohol per 210 liters of breath. There is a project underway to review “time of test” laws which specify a time in which a chemical test must be given and determine if they are scientifically sound, are working as intended and if the committee should make a recommendation about this type of law. The Committee on Alcohol and Other Drugs continues to play an active interest in drug-impaired driving by providing a forum to propose policies and recommendations through the National Safety Council that will assist in dissemination knowledge and providing guidance to scientists, legislators, government agencies and other policy-makers involved in drug-impaired driving issues. General NSC Committee meetings will now be held on a yearly basis and coincide with the American Academy of Forensic Sciences Annual Meeting. UCLA extension will be offering a course in August titled "Current Topics in Forensic Toxicology" which is sure to present valuable information. The University of Indiana will continue to offer the "Borkenstein" course with the most recent offering in May 2003.

Report: Legislative Liaison
Anne ImObersteg

The following may be of interest to the membership. For more information on these Bills, go to http://www.leginfo.ca.gov/index.html

AB 371, as amended, La Suer. Blood tests. Under existing law, only specified medical and laboratory personnel may withdraw blood for purposes of testing its alcoholic content at the request of a peace officer. These personnel include unlicensed laboratory personnel regulated under specified existing laws that provide for and determine the required qualifications for a category of "certified phlebotomy technicians." In the context of clinical laboratory work, certified phlebotomy technicians generally may not withdraw blood unless supervised by a physically available physician, and surgeon, nurse, or clinical laboratory licensee. This bill would permit a person who has been issued a "certified phlebotomy technician" certificate to withdraw blood in any location and without certain locations with general supervision, as defined, at the direction and in the presence of a peace officer, for forensic purposes regardless of whether the person is employed by a clinical laboratory. This bill would add "agencies" to those parties provided this immunity.

AB 1026, as amended, Levine. Vehicles:driving-under-the-influence: penalties. (1) Existing law requires a court to consider a concentration of alcohol in the person's blood of 0.20% or more, by weight, or the refusal of the person to take a chemical test as a special factor that may justify enhancing the penalties in sentencing, in determining whether to grant probation, and, if probation is granted, in determining additional or enhanced terms and conditions of probation, when a person is convicted of violating specified driving-under-the-influence provisions (DUI). This bill would decrease the required blood-alcohol concentration from 0.20% to 0.15%. The bill would make conforming changes in other, related provisions of law.

AB 1657, as amended, Chan. Gelatin-based alcoholic beverages. (1) The Alcoholic Beverage Control Act contains various provisions regulating the application for, the issuance of, the suspension of, and the conditions imposed upon alcoholic beverage licenses by the Department of Alcoholic Beverage Control. That act imposes additional regulations on the sale of alcoholic beverages and creates penalties for violations of those regulations. This bill would prohibit the sale, offering for sale, distribution, or import into this state of any prepackaged gelatin-based alcoholic beverage unless it is sold, offered for sale, or intended to be sold in a business establishment that prohibits the presence of persons under 21 years of age on its premises. A violation of this provision would be a misdemeanor or would subject the person to a civil action for an injunction and a civil penalty.
SB 249, as introduced, Knight. Vehicles: driving under the influence. Existing law makes it a crime for a person to drive a vehicle under the influence of alcohol or drugs or both alcohol and drugs. This bill would set forth the intent of the Legislature to enact legislation reforming the laws of the state relating to driving under the influence of alcohol or drugs or both alcohol and drugs.

SB 408, as amended, Torlakson. Vehicles: driving under the influence: driver's license sanctions. Existing law authorizes the department to impose restrictions on a person's privilege to drive, instead of a complete suspension, based upon a showing of a critical need to drive, after the department has issued an order suspending or delaying the driving privilege as a result of a violation of a specified provision prohibiting a person under the age of 21 years from driving with a blood-alcohol concentration of 0.01% or greater, as measured by a preliminary alcohol screening test or other chemical test. This bill, additionally, would require the department to determine that the person has no prior DUI convictions within 7 years of the current offense, and that the person's driving privilege has not been suspended or revoked under certain DUI provisions, prior to imposing a restriction instead of a suspension on the driving privilege. (2) Existing law provides that any document containing data prepared and maintained in the governmental forensic laboratory computerized database system that is electronically transmitted or retrieved through public or private computer networks to or by the department is the best available evidence of the chemical test results in all administrative proceedings conducted by the department. This bill, additionally, would provide that any other official record that is maintained in the governmental forensic laboratory, relates to a chemical test analysis prepared and maintained in the governmental forensic laboratory computerized database system, and is electronically transmitted and retrieved through a public or private computer network to or by the department is admissible as evidence in the department's administrative proceedings.

AB 261, as amended, Maddox. Controlled substances: dispensing or furnishing without a license. (1) Existing law makes it a misdemeanor to possess a hypodermic needle or syringe except when acquired as provided by law, and existing law makes possession of a device used for unlawful injection of controlled substances a misdemeanor, as provided. Separately, existing law provides that any person who knowingly and unlawfully dispenses or furnishes a dangerous drug or dangerous device, or who knowingly owns, manages, or operates a business that dispenses or furnishes a dangerous drug or dangerous device, without a license to dispense or furnish these products, is guilty of a misdemeanor, punishable as specified. This bill would exempt from this last provision a person who dispenses or furnishes a hypodermic syringe, needle, or similar device, and would make a violation of this provision a misdemeanor or a felony. By providing for the prosecution of the offense as a felony with its attendant prosecutorial costs, this bill would impose a state-mandated local program.

AB 1067, as amended, Shirley Horton. Nonviolent drug possession: GHB, rohypnol, and ketamine. (1) Existing law categorizes controlled substances into Schedules I to V, inclusive, and places the greatest restrictions and penalties on those contained in Schedule I. Existing law, added by initiative statute, generally provides that, effective July 1, 2001, (a) a person convicted of a nonviolent drug possession offense shall receive probation with completion of a drug treatment program as a condition of that probation, and (b) a person's parole may not be suspended or revoked for committing a nonviolent drug possession offense or for violating a drug-related condition of parole, but an additional condition of parole for those offenses or violations shall be the completion of a drug treatment program. Existing law defines the term "nonviolent drug possession offense" to include the unlawful possession, use, or transportation for personal use of any controlled substance classified in Schedules I to V, inclusive. This bill would exclude the drugs GHB, rohypnol, and ketamine, as specified, from coverage by the term "nonviolent drug possession offense." By increasing the number of people convicted of unlawful drug possession who would be subject to incarceration rather than drug treatment, this bill would impose a state mandated local program.

SB 762, as amended, Brulte. Nonviolent drug possession offense: personal use. Existing law categorizes controlled substances into Schedules I to V, inclusive, and places the greatest restrictions and penalties on those contained in Schedule I. Existing law, added by initiative statute, generally provides that, effective July 1, 2001, (a) a person convicted of a nonviolent drug possession offense shall receive probation with completion of a drug treatment program as a condition of that probation, and (b) a person's parole may not be suspended or revoked for committing a nonviolent drug possession offense or for violating a drug-related condition of parole, but an additional condition of parole for those offenses or violations shall be the completion of a drug treatment program. Existing law defines the term "nonviolent drug possession offense" to mean the unlawful possession, use, or transportation for personal use of any controlled substance classified in Schedules I to V, inclusive. Because the initiative statute may be amended by the Legislature by a 2/3 vote, the bill would require a 2/3 vote for enactment.

AB 521, as amended, Diaz. Prescription drug warnings. Existing law, the Pharmacy Law, requires a pharmacist dispensing certain prescription drugs to inform a patient, orally or in writing, of information about their harmful when taken in combination with alcohol. Existing law makes the violation of the Pharmacy Law a crime. This bill, commencing on January 1, 2005, would also require a pharmacist inform the patient the drug poses a substantial risk of harm when taken in combination with other prescription or nonprescription medication and would require that information given in writing be in at least 12-point type if the drug poses a substantial risk of harm when taken in combination with alcohol or other medications. Because a violation of this requirement would be punishable as a crime, the bill would impose a state-mandated local program.
NEW DRUGS:  Aripiprazole (Abilify®)

- Atypical Antipsychotic: Effective against both the positive and negative symptoms of schizophrenia
- Manufactured by Bristol-Myers Squibb Co. in association with Otsuka Pharmaceutical CO. Ltd. (1999)
- Tablets: 10, 15, 20 & 30 mg
- FDA Approval Letter - Nov. 15, 2002
- Quinolinone Derivative
- Structure

\[ C_{23}H_{27}Cl_2N_3O_2 \]
MW=448

- pKa = ??
- Pharmacology
- Dopamine D2 receptors
  - Presynaptic agonist
  - Postsynaptic antagonist
- Affects the 5-HT receptors
  - Antagonist at 5-HT2A
  - Partial agonist at 5-HT1A
- T1/2 46.6 hrs
- Vd 4.9 L/kg
- Levels

- Adverse Effects: Sleepiness, headache, dullness, dizziness & insomnia.
- Minimal sedation & weight gain.
- Similar to other Atypical Antipsychotics such as
  Clozapine  Quetiapine  Olanzapine
  Risperidone  Ziprasidone

**Clinical Study**

<table>
<thead>
<tr>
<th>Titrated Dose</th>
<th>Time (days)</th>
<th>Cmax (mg/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 mg/day</td>
<td>2</td>
<td>---</td>
</tr>
<tr>
<td>20 mg/day</td>
<td>2</td>
<td>---</td>
</tr>
<tr>
<td>30 mg/day</td>
<td>10</td>
<td>0.452 on day 14</td>
</tr>
</tbody>
</table>

---

Current Participation

- 39 Laboratories
- 1 from Canada
- 23 laboratories from California
- 15 from other states
- Texas - Pennsylvania
- Nevada - New Mexico
- Montana - New York
- North Carolina - Arizona
- Florida - Washington
- Michigan - Wisconsin

There is minimal amount of work involved with hosting a proficiency sample and volunteers are obviously needed to keep this program striding in the right direction. If you are interested in hosting a survey or participating in the CAT proficiency sample, please contact Dan Anderson (323) 343-0530 or email Danderso@co.la.ca.us

Webmeister Report- Alan Barbour

The CAT website, www.cal-tox.org, has been re-registered for another two years, and the URL forwarding was renewed simultaneously. URL forwarding is inexpensive and has helped to keep the web site functional even when the host server went down (which has happened twice now).

We continue to receive about 500 hits per month, and have had visitors from more than 50 countries, although the majority are naturally from the U.S..

I can normally post information sent to me for inclusion in the web site within two to three days.

The CAT Forum listserv does not seem to have any operational problems, but we continue to get occasional requests to join from non-CAT members.

The following committees report no new information:

- By-laws
- Forensic Alcohol Advisory
- Laboratory Safety
- Training Manual
Case History:
A 42-year male decedent residing with a male companion was found unresponsive on the family room couch in West Hollywood. He had an extensive history of back pain, marijuana use, and was suffering from chronic pneumonia. No foul play suspected.

Autopsy: Autopsy findings were unremarkable other than cardiovascular disease.

Cause of Death: Pending toxicological studies.

Specimens: 2 tubes 10-ml each autopsy heart blood-preserved with sodium fluoride

Sample Preparation: Drug free Porcine Blood (NaF as preservative) was supplemented with the following:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxycodone</td>
<td>0.25 ug/ml</td>
</tr>
<tr>
<td>Nevirapine</td>
<td>1.0 ug/ml</td>
</tr>
<tr>
<td>Desloratadine</td>
<td>0.50 ug/ml</td>
</tr>
</tbody>
</table>

Results:
Thirty-eight laboratories received the proficiency sample. There was a response rate of 68.4% or 26 laboratories that submitted their results. Oxycodone was detected by two of the three reference laboratories. All three-reference laboratories detected Nevirapine. Desloratadine was detected by only one of the reference laboratories and will be considered a bonus drug. Unintended results included paroxetine and Claritin®. Detailed results are listed on the excel chart.

<table>
<thead>
<tr>
<th>Count</th>
<th>Percentage</th>
<th>Result Descriptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>11.5%</td>
<td>Laboratories detected all three drugs</td>
</tr>
<tr>
<td>13</td>
<td>50%</td>
<td>Laboratories detected two of three drugs</td>
</tr>
<tr>
<td>5</td>
<td>19%</td>
<td>Laboratories detected one of three drugs</td>
</tr>
<tr>
<td>5</td>
<td>19%</td>
<td>Laboratories detected no drugs at all</td>
</tr>
<tr>
<td>20</td>
<td>77%</td>
<td>Laboratories detected Oxycodone</td>
</tr>
<tr>
<td>16</td>
<td>62%</td>
<td>Laboratories detected Nevirapine</td>
</tr>
<tr>
<td>4</td>
<td>15%</td>
<td>Laboratories detected Desloratadine</td>
</tr>
</tbody>
</table>

Proficiency Samples Objective:
- **Oxycodone** is a narcotic analgesic that has gained popularity and notoriety throughout the nation, especially with the advent of Oxycontin®. Therefore, oxycodone was supplemented in the blood at a low concentration (0.25 ug/ml) to evaluate laboratories detection limits as well as the methods employed to detect these low levels.

- **Nevirapine** or Viramune® is a non-nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents for the treatment of HIV disease. It is commonly observed in biological specimens collected from the decedent population. With a basic drug screen (liquid/liquid-back extraction or SPE), this drug can easily be detected by GC/NPD or GC/MS.

\[
C_{15}H_{14}N_4O \quad MW=266.3
\]

GC/MS: 265, 251, 133, 237, 266
• **Desloratadine** or Clarinex® is a very new, oral administered, antihistamine that is generally known as the main metabolite of loratadine or Claratin®. Desloratadine is a long-acting tricyclic histamine antagonist that is prescribed as a light blue, round, film coated tablet with 5 mg of drug.

**Chemical**

- 8-chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
- C₁₉H₁₉ClN₂
- Molecular weight 310.8
- Desloratadine is a basic drug that can be extracted with an n-butyl/chloride liquid/liquid extraction and can be detected after an acid back extraction.
- Detection of Desloratadine is possible on either a GC/NPD or GC/MS. Ions: 280, 310, 266, 245, & 230 m/z

• Relative retention time of Desloratadine (1.55/Carbinoxamine) to other commonly encountered basic drugs are as follows: Oxycodone, Norpropoxypene, Paroxetine, **DESLORATADINE**, Fentanyl, Olanzapine, Zolpidem

**Pharmacology**

- Maximum plasma concentrations (T_max): 3 hours post dose
- Half-life: 27 hours
- Extensively metabolized to 3-hydroxydesloratadine (active metabolite), which is subsequently glucuronidated.

The main objective of Desloratadine was to introduce a new drug to the Forensic Toxicology community as well inform this drug is frequently being detected in a number of postmortem cases. “Postmortem therapeutic” levels have not yet been established.
<table>
<thead>
<tr>
<th>Lab No.</th>
<th>Oxycodeone (ug/ml)</th>
<th>Method</th>
<th>Nevirapine Method</th>
<th>Desloratadine Method</th>
<th>Other Drugs Detected</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>R1, 38</td>
<td>0.27</td>
<td>GC, GC/MS</td>
<td>Present *</td>
<td>GC, GC/MS</td>
<td></td>
<td>* No Analytical Standard</td>
</tr>
<tr>
<td>R2, 26</td>
<td>0.32</td>
<td>GC/MS, LC/MS</td>
<td>Present *</td>
<td>GC/NPD, GC/MS</td>
<td></td>
<td>* No Analytical Standard</td>
</tr>
<tr>
<td>R3, 28</td>
<td>1.2</td>
<td>GC/NPD, GC/MS</td>
<td>0.54</td>
<td>GC/NPD, GC/MS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0.26</td>
<td>EIA, GC/MS</td>
<td>Present *</td>
<td>GC/NPD, GC/MS</td>
<td></td>
<td>* No Analytical Standard</td>
</tr>
<tr>
<td>2</td>
<td>0.244</td>
<td>ELISA, GC/MS</td>
<td></td>
<td></td>
<td>Two other Compounds Present</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>0.22</td>
<td>GC/NPD, GC/MS</td>
<td>Present *</td>
<td>GC/NPD, GC/MS</td>
<td></td>
<td>* By Library Match</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>0.17</td>
<td>GC/MS</td>
<td>Present *</td>
<td>GC/MS</td>
<td></td>
<td>* No Analytical Standard</td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td>See comments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No Drugs Identified</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>0.197</td>
<td>GC/NPD, GC/MS</td>
<td>Present *</td>
<td>GC/NPD, GC/MS</td>
<td></td>
<td>* Tentative ID by GC/MS</td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td>See comments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>0.18</td>
<td>GC/MS</td>
<td></td>
<td></td>
<td>Claritin 0.05</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>0.24</td>
<td>GC/MS</td>
<td>Present *</td>
<td>GC/MS, HPLC</td>
<td></td>
<td>* Not routinely quantified</td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>0.29</td>
<td>GC/NPD, GC/MS</td>
<td>Present *</td>
<td>GC/NPD, GC/MS</td>
<td></td>
<td>2 unknown peaks detected</td>
</tr>
<tr>
<td>19</td>
<td>Present *</td>
<td>ELISA, GC/NPD, GC/MS</td>
<td>Present *</td>
<td>GC/NPD, GC/MS</td>
<td>Present</td>
<td>GC/NPD, GC/MS</td>
</tr>
<tr>
<td>20</td>
<td>0.269</td>
<td>GC/NPD, GC/MS</td>
<td>Present *</td>
<td>GC/NPD, GC/MS</td>
<td>Present</td>
<td>GC/NPD, GC/MS</td>
</tr>
<tr>
<td>21</td>
<td>Present *</td>
<td>GC/NPD, GC/MS</td>
<td>Present *</td>
<td>GC/NPD, GC/MS</td>
<td></td>
<td>* Qualitative only</td>
</tr>
<tr>
<td>22</td>
<td>0.2</td>
<td>GC, GC/MS</td>
<td>0.9</td>
<td>GC, GC/MS</td>
<td>ELISA: Benzodiazepines</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>0.28</td>
<td>GC/MS</td>
<td>Present</td>
<td>GC/MS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td></td>
<td>See</td>
<td></td>
<td></td>
<td></td>
<td>No Drugs Detected</td>
</tr>
<tr>
<td>comments</td>
<td>20</td>
<td>GC, GC/MS</td>
<td>Present *</td>
<td>GC, GC/MS</td>
<td>Routine analysis not available</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>----</td>
<td>-----------</td>
<td>-----------</td>
<td>-----------</td>
<td>-------------------------------</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>Present</td>
<td>EMIT, GC/MS</td>
<td>Present *</td>
<td>GC/MS</td>
<td>* Library Search only</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>See comments</td>
<td>EMIT, GC/MS</td>
<td>Present</td>
<td>GC/MS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>0.31</td>
<td>ELISA, GC/MS</td>
<td></td>
<td></td>
<td>No Drugs detected by EIA</td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>See comments</td>
<td>ELISA, GC/MS</td>
<td></td>
<td></td>
<td>No Drugs Detected by GC</td>
<td></td>
</tr>
<tr>
<td>33</td>
<td>0.24</td>
<td>GC/MS</td>
<td></td>
<td></td>
<td>Paroxetine 1.3</td>
<td></td>
</tr>
<tr>
<td>34</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>0.25</td>
<td>EIA, GC/MS</td>
<td>Present</td>
<td>GC/MS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Target  | 0.25 | 1.0 | 0.5 |
| Range   | 0.17-0.32 | 0.9 |
| n       | 17   | 2   | 1   |
| Average | 0.242941176 | 1.05 | 0.54 |
| SD      | 0.044971478 | 0.21213203 |

**False Positives:** Claritin or Loratadine, Paroxetine
Scientific Sessions

Presentations were not received in time for publication in the Proceedings. Those received later will be published on the new Proceedings web page when it is activated within the next three months.

Friday May 2, 2003

8:30 - 9:45 Are Postmortem Blood Drug Concentrations Reliable Indicators of Toxicity?
Steven Karch, MD, Office of the Chief Medical Examiner, San Francisco, CA.

10:15 - 11:30 Postmortem Toxicology Results: They Do Usually Mean Something.
Graham Jones, Ph.D., D-ABFT, Office of the Chief Medical Examiner, Edmonton, Alberta.

11:45 - 12:30 Case Presentations from the LA County Coroner’s Laboratory.
Daniel Anderson, LA County Department of the Coroner.

1:30 - 2:45 Drugs and Driving: “What BAC is That Equivalent To?” and other implausible questions.
Barry Logan, Ph.D., D-ABFT, Washington State Patrol.

3:15 - 4:30 Cannabis Effects on Human Performance and Behavior.
Marilyn Huestis, Ph.D., National Institute on Drug Abuse.

4:30 - 5:15 Driving Under the Influence of UFOs, Demons, and the New Mexico Hot Tamale Defense: Case Presentation of Some Unique Drug-Impaired Drivers in New Mexico.
Sarah Kerrigan, Ph.D. New Mexico Department of Health.

Saturday May 3, 2003

8:30 - 9:30 CAT and SAT Business Meetings

10:00 - 12:30 Scientific Sessions

1:30 - 2:45 Scientific Sessions

3:15 - 4:30 Scientific Sessions

Lending Library Rules

1. All requests are to be made in writing to Cathy Hamm at SAN DIEGO CO MED EXAMINER, 5555 OVERLAND AVE, BLDG 14, SAN DIEGO CA 92123; 858-4995-5383 FAX, chammxmxx@co.san-diego.ca.us. Please contact the Lending Library Chair, Cathy Hamm, with your questions, including questions on how to check out materials from the Intersociety Library.

2. The Borrower will bear the cost of receiving and returning the materials borrowed. A check, covering the cost of mailing the materials to the borrower will be sent to Cathy Hamm along with the request. Cathy can give an estimate of the cost, call 858-694-2909.

3. A check of $50.00 (to cover replacement costs) will be sent with the request as a deposit for the materials borrowed (separate from the mailing costs). This check will be returned upon return of the borrowed materials.

4. Videos obtained from police agencies are for in-house viewing, and are not to be shown to the public, or used for purposes other than in-house training.

5. The Lending Library was established as a service to the members of CAT. As such, the borrower is on the “honor system,” and is expected to return borrowed materials promptly and in good condition.

6. Length of lending time for all materials is three weeks, which includes mailing time.

<table>
<thead>
<tr>
<th>CATEGORY</th>
<th>CAT LENDING LIBRARY TITLE</th>
<th>DONATED BY</th>
</tr>
</thead>
<tbody>
<tr>
<td>V</td>
<td>“Sudden Impact”, A Special Edition of Dateline NBC (drunk driving)</td>
<td>San Jose PD</td>
</tr>
<tr>
<td>V</td>
<td>The Case of the Frozen Addict (PBS 1 hr)</td>
<td>San Jose PD</td>
</tr>
<tr>
<td>V</td>
<td>Clandestine Drug Labs (59 min)</td>
<td>San Jose PD</td>
</tr>
<tr>
<td>V</td>
<td>Deadly Crystal</td>
<td>San Jose PD</td>
</tr>
<tr>
<td>V</td>
<td>Death on Ice (Fox)</td>
<td>San Jose PD</td>
</tr>
<tr>
<td>V</td>
<td>Introduction to REMEDI</td>
<td>San Jose PD</td>
</tr>
<tr>
<td>V</td>
<td>The Making of Crack Cocaine (PBS)</td>
<td>San Jose PD</td>
</tr>
<tr>
<td>V</td>
<td>Under the Influence of Crack Cocaine (15.5 min)</td>
<td>San Jose PD</td>
</tr>
<tr>
<td>V</td>
<td>Under the Influence of Crack Cocaine Update (7min)</td>
<td>San Jose PD</td>
</tr>
<tr>
<td>Topic</td>
<td>Location</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td>Under the Influence of Horein (55 min)</td>
<td>San Jose PD</td>
<td></td>
</tr>
<tr>
<td>CTC A200s Gc Autosampler/CTC HS500 Static Headspace AutoSampler</td>
<td>Leap Technologies</td>
<td></td>
</tr>
<tr>
<td>Heroin Interview (37 min)</td>
<td>San Jose PD</td>
<td></td>
</tr>
<tr>
<td>ETS Analyzer</td>
<td>P. Baughman</td>
<td></td>
</tr>
<tr>
<td>CAT Drug Interpretation Workshop 2/1/91</td>
<td>P. Baughman</td>
<td></td>
</tr>
<tr>
<td>CAT Workshop: Sample Preparation and Extraction 5/31/91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAT Meeting 2/2/91</td>
<td>TOXI-LAB</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting 5/4/91</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting 11/2/91</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting 2/7/92</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting 2/8/92</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting Training Colloquium 5/92</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Workshop 8/7/92</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting 2/93</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Workshop 5/7/93</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting 5/8/93</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting 11/93</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting 5/94</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting 8/94</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting 11/94</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting 2/95</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting 5/95</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting 11/3/95</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting 11/4/95</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Workshop &amp; Quarterly Meeting 5/3 &amp; 5/4/96</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Workshop &amp; Quarterly Meeting 8/2 &amp; 8/3/96</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Quarterly Meeting 11/2/96</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>ABUSCREEN OnTrak Product Training</td>
<td>Roche</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting (3 Tapes) 2/97</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting (3 tapes) &amp; Quarterly Meeting (3 tapes) 5/97</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting (2 tapes) 8/97</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT/SWAFTS/SATMeeting (8 tapes) 11/97</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting (4 tapes) 2/98</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Meeting February 2002</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>CAT Workshop (3 tapes) &amp; Quarterly Meeting (3 tapes) 5/98</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>Consult CAT Librarian for available tapes of CAT meetings 8/98 to present</td>
<td>CAT</td>
<td></td>
</tr>
<tr>
<td>Concepts in TDM (audio tape/slides)</td>
<td>SYVA</td>
<td></td>
</tr>
<tr>
<td>Concepts in Clinical Toxicology</td>
<td>SYVA</td>
<td></td>
</tr>
<tr>
<td>Continuing Education (tapes/slides)</td>
<td>SYVA</td>
<td></td>
</tr>
<tr>
<td>Drugs of Abuse Testing: The DPC Solution</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Micro Trak</td>
<td>HP</td>
<td></td>
</tr>
<tr>
<td>TOXI-LAB Drug Abuse Testing</td>
<td>TOXI-LAB</td>
<td></td>
</tr>
<tr>
<td>Journal: Toxicem + Krimtech 68/1 (2001)</td>
<td>Hamm, Catherine</td>
<td></td>
</tr>
<tr>
<td>CAT Membership Roster 2001-2002</td>
<td>Hamm, Catherine</td>
<td></td>
</tr>
<tr>
<td>Robert’s Rules in Plain English, Doris Zimmerman, HarperPerennial, New York</td>
<td>Hamm, Catherine</td>
<td></td>
</tr>
<tr>
<td>Reference</td>
<td>Topic</td>
<td>Publisher</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>B</td>
<td>Applications of Diode-Array Detection in HPLC</td>
<td>HP</td>
</tr>
<tr>
<td>B</td>
<td>Capillary GC: Sample Introduction Techniques</td>
<td>HP</td>
</tr>
<tr>
<td>B</td>
<td>Capillary GC: Columns and Detectors</td>
<td>HP</td>
</tr>
<tr>
<td>B</td>
<td>Capillary GC: GC/MS</td>
<td>HP</td>
</tr>
<tr>
<td>B</td>
<td>Detectors for Gas Chromatography</td>
<td>HP</td>
</tr>
<tr>
<td>B</td>
<td>Electrochemical Detection in HPLC</td>
<td>HP</td>
</tr>
<tr>
<td>B</td>
<td>GC-Atomic Emission Spectroscopy Using Microwave Plasmas</td>
<td>HP</td>
</tr>
<tr>
<td>B</td>
<td>GC Inlets - An Introduction</td>
<td>HP</td>
</tr>
<tr>
<td>B</td>
<td>High Resolution Gas Chromatography</td>
<td>HP</td>
</tr>
<tr>
<td>B</td>
<td>How To Publish a Scientific Paper</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>Individualizing Drug Therapy, Vol. 1,2,3</td>
<td>SYVA</td>
</tr>
<tr>
<td>B</td>
<td>Preparing Samples by Supercritical Fluid Extraction</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>Second Annual Symposium - Sample Preparation and Isop Using Bonded Phase</td>
<td>VARIAN</td>
</tr>
<tr>
<td>B</td>
<td>Third Annual Symposium - Sample Preparation and Isop Using Bonded Phase</td>
<td>VARIAN</td>
</tr>
<tr>
<td>B</td>
<td>Sorbent Extraction Technology</td>
<td>VARIAN</td>
</tr>
<tr>
<td>B</td>
<td>Abuscreen Programmed Learner (Basic Immunology and Radioimmunoassay)</td>
<td>Roche</td>
</tr>
<tr>
<td>B</td>
<td>Abuscreen ONTRAK User's Manual</td>
<td>Roche</td>
</tr>
<tr>
<td>B</td>
<td>Varian Sample Preparation and Products</td>
<td>VARIAN</td>
</tr>
<tr>
<td>B</td>
<td>Uppers and Downers, All Arounders</td>
<td>CINEMED</td>
</tr>
<tr>
<td>B</td>
<td>Sample Pre/Separation Using BondElute Solid Phase Extracation Columns</td>
<td>VARIAN</td>
</tr>
<tr>
<td>B</td>
<td>The Diode Array Advantage in UV/Visible Spectroscopy</td>
<td>VARIAN</td>
</tr>
<tr>
<td>B</td>
<td>Manual for Analytical Toxicology Testing</td>
<td>ROCHE</td>
</tr>
<tr>
<td>B</td>
<td>CAT Newsletter 1967-1975</td>
<td>CAT</td>
</tr>
<tr>
<td>B</td>
<td>CAT Newsletter 1975-1978</td>
<td>CAT</td>
</tr>
<tr>
<td>B</td>
<td>CAT Newsletter 1979-1981</td>
<td>CAT</td>
</tr>
<tr>
<td>B</td>
<td>CAT Newsletter 1982-1983</td>
<td>P. Baughman</td>
</tr>
<tr>
<td>B</td>
<td>CAT Newsletter 1984-1985</td>
<td>CAT</td>
</tr>
<tr>
<td>B</td>
<td>CAT Newsletter 1986-1987</td>
<td>CAT</td>
</tr>
<tr>
<td>B</td>
<td>CAT Newsletter 1987-1988</td>
<td>CAT</td>
</tr>
<tr>
<td>B</td>
<td>CAT Newsletter 1989-1990</td>
<td>CAT</td>
</tr>
<tr>
<td>B</td>
<td>CAT Newsletter 1991-1992</td>
<td>CAT</td>
</tr>
<tr>
<td>B</td>
<td>CAT Newsletter/Proceedings 1993-1994</td>
<td>CAT</td>
</tr>
<tr>
<td>B</td>
<td>CAT Newsletter 1995-1996</td>
<td>CAT</td>
</tr>
<tr>
<td>B</td>
<td>CAT Proceedings (unbound) 1997-present</td>
<td>CAT</td>
</tr>
<tr>
<td>M</td>
<td>How to Publish and Present a Scientific Paper, Design the Experiments</td>
<td>M. Huestis</td>
</tr>
<tr>
<td>M</td>
<td>Basic Principles Underlying the Collection and Statistical Treatment of Experimental Data, (paper of talk given May 1993 Workshop)</td>
<td>R.G. Gullberg</td>
</tr>
<tr>
<td>M</td>
<td>Title 8 OSHA</td>
<td>P. Baughman</td>
</tr>
<tr>
<td>M</td>
<td>Hazardous Communications Program</td>
<td>P. Baughman</td>
</tr>
<tr>
<td>M</td>
<td>Chemical Hygiene Plan</td>
<td>P. Baughman</td>
</tr>
<tr>
<td>M</td>
<td>What is ICP-MS: A guide to slides of 5/7/94 Meeting</td>
<td>P. Baughman</td>
</tr>
</tbody>
</table>


